Aldara, Zyclara (imiquimod) is a small molecule pharmaceutical. Imiquimod was first approved as Aldara on 1997-02-27. It is used to treat actinic keratosis, basal cell carcinoma, and condylomata acuminata in the USA. It has been approved in Europe to treat actinic keratosis, basal cell carcinoma, condylomata acuminata, and keratosis. It is known to target toll-like receptor 7. Aldara's patents are valid until 2030-04-30 (FDA).
|Trade Name||Aldara, Zyclara|
|Indication||actinic keratosis, basal cell carcinoma, condylomata acuminata, keratosis|